tetano
Editor, Senior Moderator
Rheumatol Int
. 2020 Aug 13.
doi: 10.1007/s00296-020-04676-4. Online ahead of print.
Coronavirus disease 2019 (COVID-19) in autoimmune and inflammatory conditions: clinical characteristics of poor outcomes
Fernando Montero[SUP] 1 [/SUP], Julia Mart?nez-Barrio[SUP] 2 [/SUP], Bel?n Serrano-Benavente[SUP] 2 [/SUP], Teresa Gonz?lez[SUP] 2 [/SUP], Javier Rivera[SUP] 2 [/SUP], Juan Molina Collada[SUP] 2 [/SUP], Isabel Castrej?n[SUP] 2 [/SUP], Jose ?lvaro-Gracia[SUP] 2 [/SUP]
Affiliations
Abstract
Objective: To describe clinical characteristics of patients with rheumatic and musculoskeletal diseases (RMDs) and immunosuppressive therapies with Coronavirus disease 2019 (COVID-19) at an academic rheumatology center in Madrid and to identify baseline variables associated with a severe infection requiring hospitalization.
Methods: We identified SARS-CoV-2 positive cases by polymerase chain reaction performed at our center within an updated RMDs database in our clinic. Additional RMDs patients were identified when they contacted the clinic because of a positive infection. Data extraction included diagnosis, demographics, immunosuppressive treatment, comorbidities, and laboratory tests. Comparisons between patients with or without hospitalization were performed. Multivariate logistic regression was used to analyze associations between baseline variables and need for hospitalization.
Results: A total of 62 patients with COVID-19 and underlying RMDs were identified by April 24, 2020. Median age was 60.9 years, and 42% men. Forty-two patients required hospitalization; these were more frequently men, older and with comorbidities. There were no statistically significant between-group differences for rheumatologic diagnosis and for baseline use of immunosuppressive therapy except for glucocorticoids that were more frequent in hospitalized patients. Total deaths were 10 (16%) patients. In multivariate analysis, male sex (odds ratio [OR], 8.63; p = 0.018), previous lung disease (OR, 27.47; p = 0.042), and glucocorticoids use (> 5 mg/day) (OR, 9.95; p = 0.019) were significantly associated to hospitalization.
Conclusion: Neither specific RMD diagnoses or exposures to DMARDs were associated with increased odds of hospitalization. Being male, previous lung disease and exposure to glucocorticoids were associated with higher odds of hospitalization in RMDs patients.
Keywords: Autoimmune diseases; COVID-19; Poor outcomes; Rheumatology.
. 2020 Aug 13.
doi: 10.1007/s00296-020-04676-4. Online ahead of print.
Coronavirus disease 2019 (COVID-19) in autoimmune and inflammatory conditions: clinical characteristics of poor outcomes
Fernando Montero[SUP] 1 [/SUP], Julia Mart?nez-Barrio[SUP] 2 [/SUP], Bel?n Serrano-Benavente[SUP] 2 [/SUP], Teresa Gonz?lez[SUP] 2 [/SUP], Javier Rivera[SUP] 2 [/SUP], Juan Molina Collada[SUP] 2 [/SUP], Isabel Castrej?n[SUP] 2 [/SUP], Jose ?lvaro-Gracia[SUP] 2 [/SUP]
Affiliations
- PMID: 32794113
- DOI: 10.1007/s00296-020-04676-4
Abstract
Objective: To describe clinical characteristics of patients with rheumatic and musculoskeletal diseases (RMDs) and immunosuppressive therapies with Coronavirus disease 2019 (COVID-19) at an academic rheumatology center in Madrid and to identify baseline variables associated with a severe infection requiring hospitalization.
Methods: We identified SARS-CoV-2 positive cases by polymerase chain reaction performed at our center within an updated RMDs database in our clinic. Additional RMDs patients were identified when they contacted the clinic because of a positive infection. Data extraction included diagnosis, demographics, immunosuppressive treatment, comorbidities, and laboratory tests. Comparisons between patients with or without hospitalization were performed. Multivariate logistic regression was used to analyze associations between baseline variables and need for hospitalization.
Results: A total of 62 patients with COVID-19 and underlying RMDs were identified by April 24, 2020. Median age was 60.9 years, and 42% men. Forty-two patients required hospitalization; these were more frequently men, older and with comorbidities. There were no statistically significant between-group differences for rheumatologic diagnosis and for baseline use of immunosuppressive therapy except for glucocorticoids that were more frequent in hospitalized patients. Total deaths were 10 (16%) patients. In multivariate analysis, male sex (odds ratio [OR], 8.63; p = 0.018), previous lung disease (OR, 27.47; p = 0.042), and glucocorticoids use (> 5 mg/day) (OR, 9.95; p = 0.019) were significantly associated to hospitalization.
Conclusion: Neither specific RMD diagnoses or exposures to DMARDs were associated with increased odds of hospitalization. Being male, previous lung disease and exposure to glucocorticoids were associated with higher odds of hospitalization in RMDs patients.
Keywords: Autoimmune diseases; COVID-19; Poor outcomes; Rheumatology.